Wedbush initiated coverage of Hemab Therapeutics, Inc. (COAG) with an Outperform rating and a price target of $42.Hemab is a clinical-stage company focused on developing subcutaneous prophylactic antibody therapies for patients with serious bleeding and thrombotic disorders. Analyst David said, "We view Hemab Therapeutics as a high conviction opportunity within rare coagulation disorders." The com...
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.